Given the lack of liver GLP-1R expression (136), the potential mechanism of actions of GLP-1R agonists in NASH may be related to the indirect beneficial effects on body weight, IR and reduction in metabolic dysfunction, lipotoxic effects and inflammation (49, 137). This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.